对氰基苯乙胺盐酸盐

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 对氰基苯乙胺盐酸盐
• 中文别名: 4-(2-氨基乙基)苯腈盐酸盐
• 英文名称: 2-(4-cyanophenyl)ethylammonium chloride
• 英文别名: 2-(4-Cyanophenyl)ethylazanium;chloride；2-(4-cyanophenyl)ethylazanium;chloride
• 化学式: C₉H₁₀N₂*ClH
• 分子量: 182.653
• InChiKey: LTYHPCKZVFOVCH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.48
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  49.8
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  对氰基苯乙胺盐酸盐 在 盐酸 、 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 N,N-二异丙基乙胺 作用下， 以 1,4-二氧六环 、 乙酸乙酯 、 N,N-二甲基甲酰胺 、 异丙醇 、 乙腈 为溶剂， 反应 2.92h， 生成 (R)-N-(4-cyanophenylethyl)-1-(6-(piperazin-1-yl)-2-(trifluoromethyl)pyrimidin-4-yl)piperidine-3-carboxamide hydrochloride
  参考文献：
  名称：

  Discovery of Trifluoromethyl(pyrimidin-2-yl)azetidine-2-carboxamides as Potent, Orally Bioavailable TGR5 (GPBAR1) Agonists: Structure–Activity Relationships, Lead Optimization, and Chronic In Vivo Efficacy

  摘要：

  Activation of the G-protein coupled receptor (GPCR) Takeda G-protein receptor 5 (TGR5), also known as G-protein bile acid receptor 1 (GPBAR1), has been shown to play a key role in pathways associated with diabetes, metabolic syndrome, and autoimmune disease. Nipecotamide 5 was identified as an attractive starting point after a high-throughput screen (HTS) for receptor agonists. A comprehensive hit-to-lead effort culminated in the discovery of 45h as a potent, selective, and bioavailable TGR5 agonist to test in preclinical metabolic disease models. In genetically obese mice (ob/ob), 45h was as effective as a dipeptidyl peptidase-4 (DPP-4) inhibitor at reducing peak glucose levels in an acute oral glucose tolerance test (OGTT), but this effect was lost upon chronic dosing.

  DOI：

  10.1021/jm401731q
• 作为产物：
  描述：

  三甲基膦酰基乙酸酯 、 4-氰基苯甲醛 在 Pd-BaSO₄ 盐酸 、 lithium hydroxide 、 TEA 、 二苯基磷酸 、 氢气 、 sodium hydride 作用下， 生成 对氰基苯乙胺盐酸盐
  参考文献：
  名称：

  D-Phe-Pro-p-Amidinobenzylamine: A potent and highly selective thrombin inhibitor

  摘要：

  The design, synthesis, and enzyme inhibitory profile of D-Phe-Pro-p-Amidinobenzylamine are presented. This compound has inhibitory activity equivalent to D-Phe-Pro-Arg-H, two orders of magnitude more potent than D-Phe-Pro-Agmatine, The results indicate that binding energy provided by the covalent bond of a transition-state analog can be replaced with noncovalent interactions. Copyright (C) 1996 Elsevier Science Ltd.

  DOI：

  10.1016/0960-894x(96)00442-8

文献信息

• [EN] P300/CBP HAT INHIBITORS<br/>[FR] INHIBITEURS D'HAT P300/CBP
  申请人：CONSTELLATION PHARMACEUTICALS INC

  公开号：WO2019161162A1

  公开（公告）日：2019-08-22

  Provided are compounds of Formula (I): and pharmaceutically acceptable salts and compositions thereof, which are useful for treating a variety of conditions associated with histone acetyltransferase (HAT).

  提供的是Formula (I)的化合物及其药用可接受的盐和组合物，可用于治疗与组蛋白乙酰转移酶（HAT）相关的各种疾病。
• Discovery of CPI-1612: A Potent, Selective, and Orally Bioavailable EP300/CBP Histone Acetyltransferase Inhibitor
  作者：Jonathan E. Wilson、Gaurav Patel、Chirag Patel、Francois Brucelle、Annissa Huhn、Anna S. Gardberg、Florence Poy、Nico Cantone、Archana Bommi-Reddy、Robert J. Sims、Richard T. Cummings、Julian R. Levell

  DOI：10.1021/acsmedchemlett.0c00155

  日期：2020.6.11

  inflammatory disorders, and neurodegeneration. A novel, highly potent, orally bioavailable EP300/CBP histone acetyltransferase (HAT) inhibitor, CPI-1612 or 17, was developed from the lead compound 3. Replacement of the indole scaffold of 3 with the aminopyridine scaffold of 17 led to improvements in potency, solubility, and bioavailability. These characteristics resulted in a 20-fold lower efficacious

  组蛋白乙酰基转移酶，CREB结合蛋白（CBP）和EP300是主要的转录共调节剂，与多种疾病有关，例如癌症，炎症性疾病和神经变性。从铅化合物3开发了一种新型的高效口服生物利用EP300 / CBP组蛋白乙酰转移酶（HAT）抑制剂CPI-1612或17。用17的氨基吡啶支架替换3的吲哚支架导致效力，溶解度和生物利用度的提高。在JEKO-1肿瘤小鼠异种移植研究中，这些特性导致17的有效剂量相对于铅3降低了20倍。
• [EN] P300/CBP HAT INHIBITORS AND METHODS FOR THEIR USE<br/>[FR] INHIBITEURS DE P300/CBP HAT ET LEURS PROCÉDÉS D'UTILISATION
  申请人：CONSTELLATION PHARMACEUTICALS INC

  公开号：WO2020176558A1

  公开（公告）日：2020-09-03

  Provided are compounds of Formula (I) : and pharmaceutically acceptable salts and compositions thereof, which are useful for treating a variety of conditions associated with histone acetyltransferase (HAT).

  提供的是化合物的化学式(I)：及其药用可接受的盐和组合物，用于治疗与组蛋白乙酰转移酶（HAT）相关的各种疾病。
• Synthesis and Study of New Quinolineaminoethanols as Anti-Bacterial Drugs
  作者：Laumaillé、Dassonville-Klimpt、Peltier、Mullié、Andréjak、Da-Nascimento、Castelain、Sonnet

  DOI：10.3390/ph12020091

  日期：——

  baumannii, Pseudomonas aeruginosa, Enterobacter spp. and Escherichia coli) bacteria. Secondly, a new series 4 was designed and assessed against the same bacteria strains, taking the pair of enantiomers 3m/3n as the lead. More than twenty compounds 4 were prepared through a five-step asymmetric synthesis with good enantiomeric excesses (>90%). Interestingly, all compounds of series 3 were efficient on

  缺乏具有与耐药菌的传播有关的新颖作用方式的抗生素，使得与传染病的斗争特别具有挑战性。喹啉核心存在于几种抗感染药中，例如甲氟喹和苯达喹啉。这项工作设定了两个主要目标。首先，我们评估了先前的喹啉3的抗分枝杆菌特性，这些喹啉已被确认为抗ESKAPEE（粪肠球菌，金黄色葡萄球菌，肺炎克雷伯菌，鲍曼不动杆菌，铜绿假单胞菌，肠杆菌属和大肠杆菌）的良好候选者。其次，设计了一个新的系列4并针对相同的细菌菌株进行了评估，以一对3m / 3n对映异构体为首。通过五步不对称合成，以良好的对映体过量（> 90％）制备了二十多种化合物4。有趣的是，系列3的所有化合物对鸟分枝杆菌均​​有效，MIC = 2–16 µg / mL，而系列4的活性较低。系列3和4通常都比甲氟喹对ESKAPEE细菌更具活性。根据全球亲脂性，喹啉4对革兰氏阳性细菌（MIC≤4 µg / mL，4c–4h和4k / 4l）或大肠杆菌（MIC =
• [EN] MTH1 INHIBITORS FOR TREATMENT OF CANCER<br/>[FR] INHIBITEURS MTH1 POUR LE TRAITEMENT DU CANCER
  申请人：THOMAS HELLEDAYS STIFTELSE FÖR MEDICINSK FORSKNING

  公开号：WO2015187088A1

  公开（公告）日：2015-12-10

  A compound of formula I, (I) or a pharmaceutically-acceptable salt thereof. The compound is useful in the treatment of cancer.

  公式I的化合物(I)或其药用可接受的盐。该化合物在治疗癌症中很有用。